Table 2.
COVID-19 Clinical Severity Outcomes and Association With Detectable RNAemia in 85 Patients
| Overall Patients (n = 85) | Detectable Plasma RNA (n = 28) | Nondetectable Plasma RNA (n = 57) | Unadjusted P Valuea | Adjusted P Valueb | |
|---|---|---|---|---|---|
| Hospital admission, no. (%) | 59 (69.4) | 22 (78.6) | 37 (64.9) | .2 | .3 |
| ICU admission, no. (%) | 17 (20.0) | 9 (32.1) | 8 (14.0) | .05 | .04 |
| Invasive mechanical ventilation, no. (%) | 8 (9.4) | 6 (21.4) | 2 (3.5) | .01 | .02 |
| 30-day all-cause mortality, no. (%) | 4 (4.7) | 4 (14.3) | 0 | .01 | ...c |
aχ 2 or Fisher’s exact test.
bLogistic regression; model adjusted for age.
cCould not be calculated given no mortality events in the nondetectable plasma RNA group.
Abbreviations: COVID-19, coronavirus disease 2019; ICU, intensive care unit.